UNI-MB - logo
UMNIK - logo
 
Fakulteta za farmacijo, Ljubljana (FFALJ)
  • Clinical evidence of the efficacy of Krkaʼs rosuvastatin in the treatment of hyperlipidemia with focus on additional doses
    Brus, Sanja
    Hyperlipidemia is associated with the highest population attributable risk for cardiovascular disease. Of various cardiovascular preventive therapies, the evidence from randomised controlled studies ... supporting the importance of aggressive lipid lowering is the most robust for statins. Clinical studies have shown that even a small reduction of LDL cholesterol has an important clinical effect. In this spirit, international guidelines recommend a Žthe lower, the betterʼ principle in the treatment of hyperlipidemia. Despite clear evidence of the benefits of statin therapy, these medicines are still underused, as shown in numerous epidemiologic studies, including the EUROASPIRE III study. In order to bridge this gap, Krka offers a wide range of rosuvastatin doses, including two intermediate doses of 15 and 30 mg. These enable treatment to be adjusted to the requirements of individual patients and result in more patients reaching target lipid levels. Krkaʼs clinical evidence, including data from the currently ongoing ROSU-PATH study, is mounting and is in favour of the use of these additional doses in everyday practice.
    Vir: Evidence-based therapy with Krka's medicines (Str. 62-71)
    Vrsta gradiva - prispevek na konferenci
    Leto - 2014
    Jezik - angleški
    COBISS.SI-ID - 3765873

Vnos na polico